



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

 INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
<i>(use as many sheets as necessary)</i>		Application Number 10/576,785	Filing Date April 21, 2006
		First Named Inventor Cheng	Art Unit _____
		Examiner Name Not yet assigned	
Sheet	1	of	2
		Attorney Docket Number 060230PCTUS	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Allison Ford/	Date Considered	10/17/2008
-------------------------------	----------------	----------------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/576,785
(use as many sheets as necessary)				Filing Date	April 21, 2006
Sheet	2	of	2	First Named Inventor	Cheng
				Art Unit	
				Examiner Name	
				Attorney Docket Number	060230PCTUS

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbers, publisher, city and/or country where published			T ²
/A.F./		DAVID S. FRANKLIN, VIRGINIA L. GODFREY, HAYOUNG LEE, GRIGORIY I. KOVALEV, ROBERT SCHOOHOVEN, SELINA CHEN-KIANG, LISHAN SU AND YUE XIONG, CDK Inhibitors p18 ^{INK4c} and p27 ^{kip1} Mediate Two Separate Pathways To Collaboratively Suppress Pituitary Tumorigenesis, Genes & Development 12, (18) 2899-2911 (1998).			
/A.F./		M.P. TSCHAN, U.R. PETERS, J.F. CAJOT, D.C. BETTICHER, M.F. FEY, AND A. TOBLER, The Cyclin-Dependent Kinase Inhibitors p18 ^{INK4c} and p19 ^{INK4a} Are Highly Expressed In CD34 ⁺ Progenitor and Acute Myeloid Leukaemic Cells But Not In Normal Differentiated Myeloid Cells, British Journal of Haematology, 644-651, (1999).			
/A.F./		SHI-JIANG LU, CHENGSHI QUAN, FEI LI, LOYDA VIDA AND GEORGE R. HONIG, Hematopoietic Progenitor Cells Derived From Embryonic Stem Cells: Analysis Of Gene Expression, Stem Cells 20, 428-437, (2002).			
/A.F./		YOUZHONG YUAN, HONGMEI SHEN, DAVID S. FRANKLIN, DAVID T. SCADDEN AND TAO CHENG, In Vivo Self-Renewing Divisions Of Haematopoietic Stem Cells Are Increased In The Absence Of The Early G1-Phase Inhibitor, p18 ^{INK4c} , Nature Cell Biology, Volume 6, Number 5, 436-442 (2004).			
/A.F./		Tao Cheng, et al, 'Transforming growth factor B1 mediates cell-cycle arrest of primitive hematopoietic cells independent of p21 ^{CDKN1A} or P27 ^{kip1} ', Blood, 15 December 2001, Vol. 98, No. 13, pp. 3643-3649.			

Examiner Signature	/Allison Ford/	Date Considered	10/17/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.